Notch Pathway Diagnostic Method Using Numb Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Aberrant Notch signaling is linked to various cancers, particularly breast cancer, with increased Notch pathway activity and decreased Numb expression, necessitating a method for diagnosing and treating cancer related to aberrant Notch pathway signaling.
Innovation Solution
A method involving the use of constructs, such as dominant negative Mastermind isoforms or Numb isoforms, in conjunction with chemotherapeutic agents, to modulate Notch pathway activity in cancer cells, and determining responsiveness based on Notch 1 and Numb expression levels, along with monitoring therapeutic regimens through gene expression analysis in the Notch signaling pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Notch pathway activity is increased in cancer cells, then tumor growth is promoted, but targeted inhibition of Notch pathway requires specific diagnostic methods to identify responsive patients
Solution Approach 1:
The patent replaces complex functional assays and mechanistic studies with a simple immunohistochemical staining method to detect Numb expression levels. This substitution allows clinical practitioners to identify Notch pathway-dependent cancer cells using routine pathology techniques rather than complex diagnostic systems, thereby resolving the contradiction between treatment reliability and diagnostic complexity
Solution Approach 2:
The patent changes the diagnostic parameter from measuring Notch pathway activity directly (which requires complex assays) to measuring Numb expression levels (which can be done via simple immunohistochemistry). This parameter change enables reliable identification of treatment-responsive patients using straightforward diagnostic methods
2Measurement precision
If Numb expression is decreased in cancer cells, then Notch signaling is upregulated promoting tumorigenesis, but determining responsiveness to Notch inhibitors requires accurate measurement of both Notch 1 and Numb expression levels
Solution Approach 1:
The patent substitutes complex molecular biology techniques (such as RT-PCR, Western blotting, or flow cytometry) with immunohistochemical staining to measure Notch 1 and Numb expression levels. This allows accurate quantification of expression levels in formalin-fixed, paraffin-embedded tissue sections using routine pathology laboratory equipment and procedures
Solution Approach 2:
The patent uses immunohistochemical staining to create visual copies of protein expression patterns in tissue sections. The stained sections provide a permanent,可视izable record of Notch 1 and Numb expression levels that can be analyzed by pathologists without requiring sophisticated measurement equipment or complex data processing
3Productivity
If dominant negative Mastermind isoforms or Numb isoforms are used to inhibit Notch pathway, then cancer cell proliferation is suppressed, but combination with chemotherapeutic agents requires careful monitoring of therapeutic response
Solution Approach 1:
The patent implements a feedback mechanism where Numb expression levels are measured before treatment to identify responsive patients, and again after treatment to monitor therapeutic response. This feedback loop allows clinicians to adjust treatment regimens based on objective biomarker changes, making combination therapy with chemotherapeutic agents more manageable and less complex
Solution Approach 2:
The patent replaces complex functional assays for monitoring therapeutic response (such as cell proliferation assays or apoptosis measurements) with simple immunohistochemical detection of Numb expression changes. This substitution makes therapeutic monitoring as easy as routine pathology while maintaining high precision in assessing treatment effectiveness
Data Source
AI summary
The present invention is based on the discovery that the Notch signaling pathway is associated with cancer. Accordingly, the invention provides methods and compositions for treating cancer. Also provided are methods of modulating the expression and/or activity of proteins in the Notch signaling pathway for use in diagnoses and treatment of cancer in a subject.